Angel Yeast plans to invest 230 million yuan to develop serum-free cell culture medium technology
May 28, 2025
Source: drugdu
74
May 26, Angel Yeast issued an announcement that it plans to implement a key technology research project for serum-free cell culture medium.
The total investment of the project is estimated at RMB 230 million, aiming to promote the development of the company's biotechnology and meet the needs of antibodies, vaccines and recombinant proteins. Other biological products The project will explore the existing synthetic biology The pilot platform has been upgraded and renovated to add a serum-free cell culture medium preparation platform and a core raw material refining and purification platform. It is expected to produce 200 tons of dry powder serum-free cell culture medium and 100,000 liters of liquid serum-free cell culture medium annually.
The project construction period is expected to be 30 months, and it is scheduled to be put into production in 2027. The funds will come from the company's own funds.
In the first quarter of 2025, Angel Yeast achieved revenue of 3.794 billion yuan and net profit attributable to shareholders of the parent company of 370 million yuan.
https://finance.eastmoney.com/a/202505263414652333.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Lepu Medical’s Sodium Hyaluronate Solution for Injection is Approved for Registration to Expand Business in the Consumer Healthcare Field July 15, 2025
- Digene Pharmaceuticals’ Suvotinib Tablets are included in the latest version of the NCCN guidelines to create a new paradigm for the internationalization of China’s “original” new drugs July 15, 2025
- Ascentage Pharmaceuticals is out with its powerful weapon July 15, 2025
- $10 billion! Merck bets on respiratory drugs July 15, 2025
- Expected to increase performance by over 40% in the first half of the year, with employee stock ownership being the first to promote high-quality development July 15, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
